FindTrial
Sign In

GT-002

DRUG2 trials

Sponsors

Region Hovedstadens Psykiatriske, Gabather AB

Conditions

Patients must meet diagnostic criteria for schizophreniaSafety and Tolerabilityacute and transient psychotic disordersinduced delusional disordersother non-organic psychotic disorders or unspecified non-organic psychosis (ICD-10: F20.x; F22.x; F23.x; F24.x; F25.x; F28; F29)persistent delusional disorderschizoaffective disorders

Phase 1

Study of Ascending Single Oral Dose of GT-002 in Healthy Volunteers
CompletedNCT03817346
Gabather ABSafety and Tolerability
Start: 2018-12-17End: 2019-05-31Updated: 2020-02-05

Phase 2

Acute Effects of Partial GABA(A)-Receptor Modulation by GT-002 on Psychophysiological Measures: The TOTEMS Phase II Clinical Trial Targeting Cognitive Impairment Associated with Schizophrenia
Not yet recruitingCTIS2024-519389-28-00
Region Hovedstadens Psykiatriskeacute and transient psychotic disorders, induced delusional disorders, other non-organic psychotic disorders or unspecified non-organic psychosis (ICD-10: F20.x; F22.x; F23.x; F24.x; F25.x; F28; F29) +3
Target: 50Updated: 2025-02-14

Related Papers

Acute effects of partial positive allosteric GABA<sub>A</sub> receptor modulation by GT-002 on psychophysiological and cognitive measures: protocol for the TOTEMS phase II trial targeting cognitive impairment associated with schizophrenia.
2025-11-25